GRAHAM E. KELLY

Corporate Board Profile

Tech Score: 0/100

MEI Pharma, Inc.

Filing Date	Source Excerpt
2004-10-28	Professor Kelly was appointed Chairman of the Board in April 2001. Professor Kelly founded Novogen in 1992 and has spent nearly 30 years in medical research involving drug development, immunology, surgery and cancer. Professor Kelly was a senior research fellow in experimental surgery in the Faculty of Medicine at the University of Sydney from 1972 to 1994 and was appointed an Adjunct Professor of the University in May 2004. He developed the ß-1, 3-Glucan and Isoflavone intellectual property now owned by Novogen and its subsidiaries.

Filing Date

Source Excerpt

2004-10-28

Professor Kelly was appointed Chairman of the Board in April 2001. Professor Kelly founded Novogen in 1992 and has spent nearly 30 years in medical research involving drug development, immunology, surgery and cancer. Professor Kelly was a senior research fellow in experimental surgery in the Faculty of Medicine at the University of Sydney from 1972 to 1994 and was appointed an Adjunct Professor of the University in May 2004. He developed the ß-1, 3-Glucan and Isoflavone intellectual property now owned by Novogen and its subsidiaries.

Data sourced from SEC filings. Last updated: 2026-02-03